Our commitments

We have 23 forward-looking commitments across the four areas of our responsible business approach.

They aim to address unmet global health needs and are aligned with our strategic priorities and our values.

Each year we report on our progress against these commitments and here we provide a summary for those that relate to Our behaviour.

 

Ethical Conduct

We will contiune to strengthen our values based culture by training our people on the standards expected, encouraging the reporting of any concerns and embedding our values into the way we measure employee performance.

Progress: Progressing well

99.9% of employees completed mandatory annual training on our Code of Conduct. Extended the training to over 30,600 complementary workers. Strengthened training, with external certification, for members of our Ethics and Compliance team.

Close

Promoting values in sales and marketing practices

Continue to drive a values-based approach to sales and marketing practices across the world, with the interests of consumers and patients at its core.

Progress: Progressing well 

Completed the global roll-out of changes to sales team compensation. No longer pay healthcare professionals to speak to other prescribers about our medicines.

Close

Rigorous patient and consumer safety

Continue to ensure the interests and safety of patients and consumers are of paramount importance in the way we design and undertake our clinical trials, our product quality assurance and our monitoring and reporting of adverse events in ongoing product usage.

Progress: Progressing well

Recognised for our collaboration with informatics company, Epidemico, to monitor publicly available information on social media to gain insights into the adverse effects of our medicines. Extended our supply chain serialisation programme, Fingerprint, across 86 packaging lines toverify products anywhere in the supply chain and help to combat counterfeiting.

Close

Minimising animal testing

Rigorously challenge the need for animal studies and work to minimise the impact on animal welfare, by investing in the development of alternative studies and sharing animal-based data.

Progress: Progressing well

Used 26% fewer animals than in 2014, a continuation of a downward trend over nine years. 98% of animals used were rodents.

Close

Promoting Human Rights

Address the UN Guiding Principles on Human Rights and Business across our own operations and our supplier relationships.

Progress: On track

Labour rights included in comprehensive new programme to strengthen our management of third party risks in the supply chain. Became a Living Wage accredited employer in the UK.

Close

Transparency in clinical trial data

Be as transparent as possible with our clinical trial data, including publishing clinical study reports (without patient-level data) for all outcome trials of medicines conducted by GSK and, within an appropriate process, making available to researchers access to anonymised patient level data to further scientific enquiry.

Progress: Complete

The Wellcome Trust took over the management of the panel of external independent experts that review proposals to access data on www.clinicalstudydatarequest.com, an important step towards creating an independent data-sharing system that includes studies from across industry and academia. In 2015 we also met our commitment to make available global studies going back to the formation of GSK in 2000 – 1,700 studies in all.

Close

Ensuring ethical stakeholder interactions

Demonstrate that all GSK interactions with patient advocacy groups and political stakeholders are conducted appropriately, ethically and transparently.

Progress: Progressing well

Ranked in the top three most transparent FTSE 100 companies by Transparency International in their Corporate Political Engagement Index. Produced a new Global Standard for Interactions with Patient Organisations.

Close

Working with third parties

We seek to work with third parties that share our commitment to high ethical standards and operate in a responsible way. If performance gaps are identified, where appropriate we commit to working with the third party to improve performance.

Progress: On track 

Introduced a comprehensive new programme to strengthen our management of third party risks in the supply chain. Identified over 1,300 high-risk suppliers that must undergo an assessment of responsible business policies and practices. Assessed around 200 high-risk distributors.

Close